(Q42984424)

12 November 2017

title

Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population? (English)

1 reference

12 November 2017

1 reference

Gerry C Macquillan

1

1 reference

12 November 2017

Xianwa Niu

2

1 reference

12 November 2017

David Speers

3

1 reference

12 November 2017

Suzanne English

4

1 reference

12 November 2017

George Garas

5

1 reference

12 November 2017

Gerry B Harnett

6

1 reference

12 November 2017

William D Reed

7

1 reference

12 November 2017

Jane E Allan

8

1 reference

12 November 2017

Gary P Jeffrey

9

1 reference

12 November 2017

publication date

1 May 2004

1 reference

Journal of Gastroenterology and Hepatology

12 November 2017

published in

1 reference

12 November 2017

volume

19

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

551-557

1 reference

Hepatitis C virus and organ transplantation

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2003.03319.X

10.1111/J.1440-1746.2003.03319.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference